HSP For Use in Treatment for Imiquimod Related Side Effects

Healthcare product according to any one of the preceding claims, wherein the healthcare product contains a first container containing a first healthcare composition comprising the heat shock protein or heat shock protein hydrolysate and a second container containing a second healthcare composition comprising imiquimod.

Healthcare product according to any one of the preceding claims, wherein the heat shock protein or heat shock protein hydrolysate is present in a total concentration of 5-1000 μg per mL of the composition in which it is present, in particular of 20-600 μg per mL of healthcare product.

Healthcare product according to any one of the preceding claims, wherein the concentration of imiquimod is in the range of 0.1-10 wt. %.

Healthcare product according to any of the preceding claims for use in the prophylactic or therapeutic treatment of a skin disorder, preferably a skin disorder selected from the group of acne, warts, athlete's foot, Lyme disease, psoriasis, lichen, ichthyosis, keratosis, Darier's disease, pustulosis, herpes zoster, cellulitis, eczema (such as atopic dermatitis), neurodermatitis, herpes, inflammatory skin disorders, skin cancers and children's diseases affecting the skin (such as varicella, rubella, measles).

A heat shock protein, preferably a Hsp 70, more preferably alfalfa Hsp, for use in preventing the occurrence of a negative-side effect of a treatment with imiquimod, or alleviating such side effect.